Mosunetuzumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.

**Synonyms:** - Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A - BTCT 4465A - BTCT-4465A - BTCT4465A - CD20/CD3 BiMAb BTCT4465A - Lunsumio - MOSUNETUZUMAB - Mosunetuzumab-axgb - RG 7828 - RG-7828 - RG7828 - RO7030816